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CC BY-NC-ND license (http://creativeAbstract While CRISPR/Cas9-mediated genome editing technology has been experiencing a
rapid transformation during the past few years, a recent report on NgAgo-mediated single-
stranded DNA-guided genome editing may offer an attractive alternative for genome manipu-
lation. While it’s too early to predict whether NgAgo will be able to compete with or be supe-
rior to CRISPR/Cas9, the scientific community is anxiously waiting for further optimization and
broader applications of the NgAgo genome editing technology.
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an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).With the rapid progress being made in genome sciences,
effective genome engineering holds great promise both in
understanding the molecular bases of human diseases and in
treating human disorders with identifiable alterations in the
genome. Since the advent of the effective but clumsy zinc-
finger nuclease-based TALEN (transcription activator-like
effector nucleases) technology,1e3 we have been searching
for simple and effective approaches for genome manipula-
tion. The past few years have witnessed a rapid rise of the
RNA-guided CRISPR/Cas9 technology from obscurity.4e8
CRISPRs (Clustered Regularly-Interspaced Short Palindromic
Repeats) are segments of prokaryotic DNA containing short
sequence repetitions, while bacterial endonuclease Cas9 can
beprogramedbya small guide RNA (gRNA) to inducea double-
strand break at a desired genomic locus that is followed by a
protospacer-adjacent motif (PAM).9 The resulting double-
strand break can either be repaired by homology-directed
repair (HDR) or by non-homologous end joining (NHEJ),
which is usually imprecise, resulting in small insertions or
deletions (indels).4,7 This technology has been widely used to
rapidly generate gene knockouts in various organisms. Sig-
nificant efforts are being devoted to optimizing the currentity of Chongqing Medical
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commons.org/licenses/by-nc-nd/CRISPR/Cas9 system and/or to identifying more Cas9-like
nucleases with better efficiency and specificity.7,10e12
However, a recent report might have changed the land-
scapeof genomeediting technologies.13Gao F., et al identified
a member of the Argonaute endonuclease family, called
Natronobacterium gregoryi Argonaute (NgAgo), which was
shown to effectively carry out DNA-guided genome editing in
mammalian cells.13 The Argonautes are a family of endonu-
cleases that use 50-phosphorylated short single-stranded
nucleic acids as guides to cleave targets.14,15 Argonaute pro-
teins play an important role in RNA interference andmicroRNA
processing.14,16 Several Argonautes isolated fromthermophiles
can use single-stranded (ss) DNA guides to cleave DNA targets
at high temperature.17e19 In their study, Gao F., et al demon-
strated that the NgAgo endonuclease was able to bind 50-
phosphorylated single-stranded guide DNA (gDNA) ofw24 nu-
cleotides andefficiently generate gDNA sequence-specificDNA
double-stranded breaks at 37 C. This editing process did not
require the presence of PAM. NgAgo was shown to remove
several nucleotides in the target region, although it seemingly
does not have any exonuclease activity.13 By assessing the
ability of 47 different ssDNA guides targeting eight genes in the
human genome, the authors reported 21e41% targeting effi-
ciencies among all guides tested. The authors subsequently
demonstrated that the NgAgoegDNA system exhibited a lowand hosting by Elsevier B.V. This is an open access article under the
4.0/).
170 Perspectivestolerance to guideetarget mismatches, as mismatches be-
tween the ssDNA guide and target reduced the efficiency of
cleavage. A comprehensive analysis of singlemismatches at all
24 positions revealed that all positions were important, with
positions 8e11 being particularly important, and that the
presence of three consecutive mismatches eliminated all ac-
tivity.13 The authors further showed that NgAgo, unlike
CRISPR/Cas9, was highly efficient in editing almost any
sequence, including G/C-rich genomic sequences.13
While still at an early development stage, NgAgo has the
following distinctions and potential advantages over the
CRISPR/Cas9 system: (1) NgAgo utilizes 50-phosphorylated
ssDNA guides (w24 bp) to cleave supercoiled DNA; (2)
mammalian cells have very low levels of 50P-ssDNA, elimi-
nating the possible presence of off-target guides for NgAgo;
(3) NgAgo is seemingly more specific than Cas9, as it
completely loses activity when there are three mismatches;
(4) NgAgo was about as effective as, if not more effective
thanCas9 for DNAcleavage inmammalian cells; (5) NgAgo is a
smaller protein, which is easier to express; and (6) NgAgo
does not require a PAM and can target GC-rich genomic loci
with high efficiency. Nonetheless, much more needs to be
learned about the NgAgo system before any conclusions can
bedrawnabout its potential applications.While the use of 50-
phosphorylated ssDNA as a guide provides a simple and
convenient means for in vitro cell-based genome editing,
this may limit NgAgo’s utility for in vivo genome engineering
unless approaches for efficient and targeted delivery of
ssDNA guides are devised. It remains to be fully investigated
whether NgAgo can effectively mediate homology-directed
recombination with similar or better efficiency compared
with CRISPR/Cas9. Structure-function studies of NgAgo may
further optimize its genome editing activity. It’s conceivable
thatmore NgAgo-like proteinswill be found in future studies.
For much of the scientific community however it is not
important to determine whether NgAgo will out-compete
CRISPR/Cas9, or vice versa. We are thrilled to have another
cool tool in the genome engineering toolkit.
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